ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,870.62
      -1.32%
      US Tech 100
      19,880.00
      -2.30%
      Dow Jones
      43,444.99
      -0.70%
      Brent Oil
      70.895
      0.00%
      Bitcoin
      91,569.87
      0.56%
      Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. Merus NV (MRUS) Quote

      Merus NV

      Merus NV (MRUS)

      NASDAQ
      46.58
      -3.08
      (-6.20%)
      Closed November 16 4:00PM
      Delayed by 15 minutes
      46.58
      0.01
      (0.02%)
      After Hours: 7:33PM
      Delayed by 15 minutes

      Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

      Premium

      Key stats and details

      Current Price
      46.58
      Bid
      45.10
      Ask
      54.22
      Volume
      585,424
      46.045 Day's Range 49.22
      22.26 52 Week Range 61.61
      Market Cap
      3.189B
      Previous Close
      49.66
      Open
      49.22
      Last Trade
      1
      @
      46.58
      Last Trade Time
      Financial Volume
      $ 27,753,504
      VWAP
      47.4075
      Average Volume (3m)
      466,340
      Shares Outstanding
      68,463,681
      Dividend Yield
      -
      PE Ratio
      0.00
      Earnings Per Share (EPS)
      -
      Revenue
      43.95M
      Net Profit
      -154.94M

      About Merus NV

      Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics. Merus only reportable segment comprising the discovery and development of innovative ... Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics. Merus only reportable segment comprising the discovery and development of innovative bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others. Show more

      Sector
      Gen Med & Surgical Hospitals
      Industry
      Gen Med & Surgical Hospitals
      Website
      www.merus.nl
      Headquarters
      Utrecht, Utrecht, Nld
      Founded
      -
      Merus NV is listed in the Gen Med & Surgical Hospitals sector of the NASDAQ with ticker MRUS. The last closing price for Merus NV was $49.66. Over the last year, Merus NV shares have traded in a share price range of $ 22.26 to $ 61.61.

      Merus NV currently has 68,463,681 shares outstanding. The market capitalization of Merus NV is $3.40 billion.

      Ask ADVFN Intelligence (AI)

      Merus NV (MRUS) Options Flow Summary

      MRUS Options Flow

      Overall Flow

      Bullish

      Net Premium

      117k

      Calls / Puts

      100.00%

      Buys / Sells

      0.00%

      OTM / ITM

      100.00%

      Sweeps Ratio

      0.00%

      MRUS Latest News

      More News

      Form 8-K - Current report

      November 05 2024
      Edgar (US Regulatory)

      Merus Receives FDA extension of PDUFA for zenocutuzumab

      UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing...

      November 05 2024
      GlobeNewswire Inc.

      Merus Announces Financial Results for the Third Quarter 2024 and Provides Business Update

      Phase 3 registrational trials evaluating petosemtamab in combination with pembrolizumab in 1L and petosemtamab monotherapy in 2/3L r/m HNSCC enrolling Petosemtamab in 2L+ r/m HNSCC interim...

      October 31 2024
      GlobeNewswire Inc.

      Form 10-Q - Quarterly report [Sections 13 or 15(d)]

      October 31 2024
      Edgar (US Regulatory)

      Merus Announces First Patient Dosed in LiGeR-HN1, a Phase 3 Trial Evaluating Petosemtamab in Combination with Pembrolizumab in 1L r/m HNSCC

      UTRECHT, The Netherlands and CAMBRIDGE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing...

      September 30 2024
      GlobeNewswire Inc.

      Merus Announces Abstract Accepted for Presentation at the ESMO Asia Congress 2024

      UTRECHT, The Netherlands and CAMBRIDGE, Mass., Sept. 17, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing...

      September 17 2024
      GlobeNewswire Inc.

      Form 4 - Statement of changes in beneficial ownership of securities

      August 22 2024
      Edgar (US Regulatory)

      Merus to Present at Canaccord Genuity’s 44th Annual Growth Conference

      UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific...

      August 06 2024
      GlobeNewswire Inc.

      Merus Announces Financial Results for the Second Quarter 2024 and Provides Business Update

      – Petosemtamab in combination with pembrolizumab interim data presented at 2024 ASCO® demonstrated robust 67% response rate among 24 evaluable patients – First patients dosed in phase 3 trial...

      August 01 2024
      GlobeNewswire Inc.

      Form 10-Q - Quarterly report [Sections 13 or 15(d)]

      August 01 2024
      Edgar (US Regulatory)
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      1-7.96-14.594792812654.5455.009946.5730735252.11662238CS
      4-5.12-9.9032882011651.755.3946.5735715352.14653289CS
      12-6.92-12.934579439353.555.3946.5746634050.97896658CS
      261.032.2612513721245.5561.6142.672292553.34199152CS
      5222.5293.599334995824.0661.6122.2664728547.08656816CS
      15617.2358.705281090329.3561.6112.0341557434.88957244CS
      26030.59191.30706691715.9961.6110.1832201331.81531959CS

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      CEROCERo Therapeutics Holdings Inc
      $ 0.2853
      (52.40%)
      		1.17B
      CYCNCyclerion Therapeutics Inc
      $ 2.5306
      (42.97%)
      		11.99M
      SPPLSIMPPLE Ltd
      $ 1.2503
      (41.60%)
      		165.69M
      PULMPulmatrix Inc
      $ 6.5586
      (39.54%)
      		5.37M
      ZTEKZentek Ltd
      $ 1.2574
      (29.96%)
      		309.67k
      TFFPTFF Pharmaceuticals Inc
      $ 0.376101
      (-76.49%)
      		9.35M
      EYENEyenovia Inc
      $ 0.10185
      (-70.05%)
      		52.8M
      CTXRCitius Pharmaceuticals Inc
      $ 0.1974
      (-39.89%)
      		11.26M
      VVPRVivoPower International PLC
      $ 0.8151
      (-39.62%)
      		2.34M
      IPWiPower Inc
      $ 0.7302
      (-39.15%)
      		1.15M
      CEROCERo Therapeutics Holdings Inc
      $ 0.2853
      (52.40%)
      		1.17B
      ELABElevai Labs Inc
      $ 0.0211
      (-19.47%)
      		380.03M
      NVDANVIDIA Corporation
      $ 141.98
      (-3.26%)
      		253.02M
      SPPLSIMPPLE Ltd
      $ 1.2503
      (41.60%)
      		165.69M
      STISolidion Technology Inc
      $ 0.44
      (25.71%)
      		140.02M

      MRUS Discussion

      View Posts
      Monksdream Monksdream 2 months ago
      MRUS range bound
      👍️0
      Phosphene Phosphene 4 years ago
      Merus and myTomorrows Announce Expansion of Collaboration for Screening and eNRGy Clinical Trial Awareness for Cancer Patients with Neuregulin 1 Fusion Tumors

      https://www.globenewswire.com/news-release/2020/10/12/2107078/0/en/Merus-and-myTomorrows-Announce-Expansion-of-Collaboration-for-Screening-and-eNRGy-Clinical-Trial-Awareness-for-Cancer-Patients-with-Neuregulin-1-Fusion-Tumors.html
      👍️0
      Phosphene Phosphene 4 years ago
      The Baker Brothers have 7% ownership.

      https://whalewisdom.com/filer/baker-bros-advisors-llc#tabholdings_tab_link
      👍️0
      Phosphene Phosphene 4 years ago
      Board Member: Victor Sandor

      https://ir.merus.nl/board-member/victor-sandor

      https://www.businesswire.com/news/home/20200824005127/en/Prelude-Therapeutics-Announces-Closing-50M-Series-Financing
      👍️0
      Phosphene Phosphene 4 years ago
      Second Quarter 2020 Results:

      https://www.globenewswire.com/news-release/2020/08/06/2074649/0/en/Merus-Announces-Financial-Results-for-the-Second-Quarter-and-Provides-Business-Update.html
      👍️0
      Phosphene Phosphene 4 years ago
      https://merus.nl/
      👍️0
      Phosphene Phosphene 4 years ago
      European cancer biotech Merus nabs Sanofi I-O chief Andrew Joe

      https://www.fiercebiotech.com/biotech/european-cancer-biotech-merus-nabs-sanofi-i-o-chief-andrew-joe
      👍️0

      Your Recent History

      NASDAQ
      MRUS
      Merus NV
      Delayed Upgrade Clock